Alnylam Pharmaceuticals Inc $55.26

up +1.15


22/7/2014 04:00 PM  |  NASDAQ : ALNY  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get ALNY Trend Analysis - it has outperformed the S&P 500 by 7%

Partner Headlines

  1. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  2. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga
  3. Alnylam Pharma

    IBD
  4. Alnylam Presents Pre-Clinical Data on RNAi Therapeutics at ISA

    Benzinga
  5. UPDATE: Alnylam, Collaborators to Offer New Clinical Data for Patisiran

    Benzinga
  6. UPDATE: Alnylam Receives Positive Opinion for Orphan Drug Designation in ...

    Benzinga
  7. Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a Subcutaneously ...

    Benzinga
  8. UPDATE: Morgan Stanley Downgrades Alnylam Pharmaceuticals, Sees Robust ...

    Benzinga
  9. Benzinga's M&A Chatter for Monday January 13, 2014

    Benzinga
  10. Market Wrap For January 13: Markets Showing Weakness Ahead Of Major Earning ...

    Benzinga
  11. Mid-Afternoon Market Update: Markets Dip Despite Large Amount of M&A

    Benzinga
  12. Mid-Day Market Update: SodaStream Drops After Weak Outlook; Beam Shares ...

    Benzinga
  13. Mid-Morning Market Update: Markets Open Lower; Lululemon Lowers Q4 Outlook

    Benzinga
  14. UPDATE: JMP Securities Reiterates Market Perform on Alnylam Pharmaceuticals ...

    Benzinga
  15. Morning Market Movers

    Benzinga
  16. Stocks Futures Mildly Lower; Lululemon, Ascena Pare Guidance

    IBD
  17. Benzinga's Top #PreMarket Gainers

    Benzinga
  18. US Stock Futures Fall Ahead Of Federal Budget

    Benzinga
  19. Genzyme, Alnylam Expand Collaboration on Rare Genetic Diseases

    Benzinga
  20. Alnylam Acquires Sirna Therapeutics from Merck for $175M Upfront Payment ...

    Benzinga
  21. Tekmira Receives $5M Milestone Payment from Alnylam

    Benzinga
  22. Alnylam Presents New Pre-clinical Data on ALN-AT3 for Treatment of Hemophilia ...

    Benzinga
  23. Alnylam Earns $7M Milestone Payment from Partner Genzyme for Phase II Success ...

    Benzinga
  24. Alnylam Presents New Pre-clinical Data on RNAi Therapeutics at American ...

    Benzinga
  25. Alnylam Announces Positive Phase II Data for Patisiranfor for Treatment ...

    Benzinga
  26. Alnylam Presents New Pre-clinical Data on ALN-AAT

    Benzinga
  27. The Medicines Company, Alnylam Announce Advance Development Candidate ...

    Benzinga
  28. Alnylam Pharma Announces Advancement of Development Candidate for ALN-AS1

    Benzinga
  29. Pharmaceutical Industry Expected To Collect Billions From Obamacare

    Benzinga
  30. Alnylam Closes Enrollment of Phase II Clinical Trial and Initiates Study ...

    Benzinga
  31. Alnylam Announces Positive Interim Results from Phase I Clinical Trial ...

    Benzinga
  32. Alnylam Confirms Added Orphan Drug Status for ALN-AT3

    Benzinga
  33. Alnylam Confirms Orphan Drug Status for ALN-AT3, RNAI for Hemophilia Treatment

    Benzinga
  34. Jefferies Reiterates Buy Rating, $34 PT on Partnership with Alnylam Pharmaceuticals

    Benzinga
  35. A Peek Into The Market Before The Trading Starts

    Benzinga
  36. The Medicines Company, Alnylam Announce Global Alliance

    Benzinga
  37. Alnylam Pharma Offer Results from Phase I Trial, Extension Study with ALN-VSP

    Benzinga
  38. UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Alnylam ...

    Benzinga
  39. Alnylam Pharma Announces Exercise of Underwriter's Over-Allotment Option ...

    Benzinga
  40. Alnylam Pharmaceuticals Prices 8M Share Offering at $20.13/Share

    Benzinga
  41. Alnylam Pharmaceuticals Prices 8M Share Offering at $20.13/Share

    Benzinga
  42. Alnylam Pharma Reports Offering of $125M in Stock

    Benzinga
  43. Alnylam Shares Higher Following New Pre-clinical Data on RNAi Therapeutics ...

    Benzinga
  44. Alnylam, Tekmira Resolve All Litigation; Alnylam to Make $65M One-Time ...

    Benzinga
  45. Isis Pharmaceuticals To Receive $1.1 Million From Alnylam

    Benzinga
  46. Alnylam Presents Complete Results from Phase IIb Trial on ALN-RSV01 with ...

    Benzinga
  47. Isis Pharma to Receive $1.4M from Alnylan

    Benzinga
  48. Regulus Files Registration Statement for Proposed Initial Public Offering

    Benzinga
  49. Myriad Genetics Patents Upheld, But Fight Not Over

    IBD
  50. Myriad Genetics Earnings Expected To Stay On Rebound

    IBD
Trading Center